{"id":"W4413791306","doi":"10.1016/s2152-2650(25)02276-1","title":"ABCL-544: Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Oxaliplatin; Diffuse large B-cell lymphoma; Internal medicine; Refractory (planetary science); Oncology; Lymphoma; Phases of clinical research; Clinical trial; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001585712,0.0009829857,0.001754095,0.0003077349,0.0002471744,0.001190291,0.0006727037,0.0008571371,0.001799079],"category_scores_gemma":[0.0007671458,0.0003250418,0.001707676,0.0004274778,0.0007927347,0.001174879,0.0004954824,0.002117189,0.0006363923],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001020047,"about_ca_system_score_gemma":0.0008369077,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001211863,"about_ca_topic_score_gemma":0.002885906,"domain_scores_codex":[0.9995847,0.0002039755,0.00001994747,0.00006224118,0.00003050524,0.00009859972],"domain_scores_gemma":[0.9995096,0.0000727275,0.0001206376,0.00004352032,0.00002244867,0.0002311961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8106918,0.008920148,0.01720694,0.0007250009,0.003550112,0.0002027358,0.000244412,0.004062776,0.009197845,0.0003738242,0.006824947,0.1379995],"study_design_scores_gemma":[0.6331478,0.2773451,0.07006221,0.0001385287,0.002863265,0.0008117827,0.0003026754,0.003851388,0.003000278,0.001113001,0.007278394,0.00008548647],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937991,0.003499973,0.0001548481,0.0005495232,0.000107297,0.0001768652,0.0006504869,0.00007285184,0.0009889564],"genre_scores_gemma":[0.9927007,0.00199179,0.0004308602,0.0008902181,0.00009406671,0.0002155351,0.002357789,0.00002318295,0.001295861],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001799079,"threshold_uncertainty_score":0.008386135,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01368131814800245,"score_gpt":0.2893786092430847,"score_spread":0.2756972910950823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}